当风险分成收入在公司确认能否承担结果前就签订，利润与现金就会背离。 数字健康公司面临的问题版本并非通用版。结果风险签订速度快于公司了解自身能否承担的速度——12个月测量窗口对11个月销售周期——因此忽略风险分成收入的答案会自信地出错。分析必须从参与率和毛利率而非收入开始。
当风险分成收入在公司确认能否承担结果前就签订，利润与现金就会背离。 数字健康公司面临的问题版本并非通用版。结果风险签订速度快于公司了解自身能否承担的速度——12个月测量窗口对11个月销售周期——因此忽略风险分成收入的答案会自信地出错。分析必须从参与率和毛利率而非收入开始。
一家盈利的数字健康企业会在承担结果风险前耗尽现金：风险分成提前承诺、按人头付费提前支付、收入提前入账，却在客户流失显示毛利率是否稳固前。
重要后果是，在此情况下增长会让问题恶化而非改善。每增加一份合同都会扩大缺口，这就是为什么快速增长的盈利企业会出现ARR上升、会员基数扩大却仍失败。
杠杆平实且见效快：风险分成条款、结果测量延迟、与参与里程碑挂钩的分阶段付款，以及按验证结果而非预测管理已注册会员。这些通常比任何融资对话更快释放更多现金。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 损益表显示来自风险合同的健康ARR，但银行余额并未随之变动。
✓ 风险分成上升，却未匹配确认参与率或归因结果的上升。
✓ 新客户增加和会员增长期总是与现金压力同时出现。
通常会让情况更糟的做法。 在不弥合缺口的情况下融资填补，将结果风险问题转化为利息支出，并让风险机制继续运行。
It is for you if you run or finance a digital health company and the P&L looks healthy and the bank balance does not. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Proprietary EFF Methodology, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
因为利润在开票时确认，现金在人们付款时移动。两者之间的差距乘以增长，就是增长消耗的现金量。
通常是开票延迟和定金，因为两者都在您的控制范围内且立即生效。追讨欠款有帮助但更慢；重新谈判供应商条款有帮助但更慢。
仅在同时弥合缺口时。融资结构性营运资金周期而不改变周期，意味着下一次增长时将以更差条件再次借贷。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית